Hemophilia Therapeutics Pipeline to Witness Major Collaborations in The Future
© Kumar Vin
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis
The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route.
Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis/report-sample
Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In September 2016, Roche in collaboration with Chugai Pharmaceutical Co. Ltd. initiated a Phase III trial to evaluate the safety, pharmacokinetics and efficacy of prophylactic subcutaneous emicizumab in patients (aged 12 years) suffering from hemophilia A without factor VIII inhibitors.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hemophilia-therapeutics-pipeline-analysis
Many drug candidates received USFDA designations namely Orphan, Fast Track or Breakthrough designations in their clinical stages for the treatment of hemophilia. In August 2016, Orphan Drug Designation was granted to Phase III drug candidate of Chugai Pharmaceuticals, by Ministry of Health, Labour and Welfare, Japan.
Some of the key players developing drugs for the treatment of hemophilia include Sangamo BioSciences, Inc., Caisson Biotech, Inc., XL-protein GmbH, and others.
Hemophilia Pipeline Analysis
• By Phase
• By Route of Administration
• By Molecule Type
• By Company
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
• Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
• Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Access Report Overview: https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis
The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route.
Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis/report-sample
Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In September 2016, Roche in collaboration with Chugai Pharmaceutical Co. Ltd. initiated a Phase III trial to evaluate the safety, pharmacokinetics and efficacy of prophylactic subcutaneous emicizumab in patients (aged 12 years) suffering from hemophilia A without factor VIII inhibitors.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hemophilia-therapeutics-pipeline-analysis
Many drug candidates received USFDA designations namely Orphan, Fast Track or Breakthrough designations in their clinical stages for the treatment of hemophilia. In August 2016, Orphan Drug Designation was granted to Phase III drug candidate of Chugai Pharmaceuticals, by Ministry of Health, Labour and Welfare, Japan.
Some of the key players developing drugs for the treatment of hemophilia include Sangamo BioSciences, Inc., Caisson Biotech, Inc., XL-protein GmbH, and others.
Hemophilia Pipeline Analysis
• By Phase
• By Route of Administration
• By Molecule Type
• By Company
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
• Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
• Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com